Clinical trials: Node Positive Breast Cancer
Triple Negative Breast Cancer, Breast Neoplasms
Vaccination of Triple Negative Breast Cancer Patients
The purpose of this study is to evaluate a new investigational cancer vaccine, P10s-PADRE in combination with standard neoadjuvant chemotherapy and surgery in patients with clinical stage I, II or III triple negative breast…
- Trial name
- NCT02938442
- Testing
- P10s-PADRE with MONTANIDE™ ISA 51 VG, Doxorubicin, Cyclophosphamide
- Where
- 2 sites in United States
- Volunteers
- 16 people
- Sponsor
- University of Arkansas
Hormone Receptor Positive Breast Cancer
A Global Study to Compare the Effects of Fulvestrant and Arimidex in a Subset of Patients With Breast Cancer.
The purpose of the study is to compare how treatment with Fulvestrant (FASLODEX) or Anastrozole (ARIMIDEX) effects disease progression for women with locally advanced or metastatic breast cancer who have not had prior hormonal…
- Trial name
- FALCON (NCT01602380)
- Testing
- faslodex 500mg, arimidex 1mg, faslodex dummy
- Where
- 118 sites in United States, Argentina and 18 more
- Volunteers
- 462 people
- Sponsor
- AstraZeneca
Adenocarcinoma, Gastric, Neoplasm, Breast
DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein
HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells.
- Trial name
- NCT03368196
- Testing
- DS-8201a
- Where
- 2 sites in Taiwan
- Volunteers
- 12 people
- Sponsor
- Daiichi Sankyo Taiwan Ltd., a Daiichi Sankyo Company
Neoplasms, Breast
Lapatinib for Brain Metastases In ErbB2-Positive Breast Cancer
Determine how safe and effective lapatinib is when used to treat patients with ErbB2 overexpressing breast cancer that has spread to the brain and is still progressing there even after radiation treatment using WBRT (whole brain…
- Trial name
- NCT00263588
- Testing
- lapatinib
- Where
- 74 sites in United States, Australia and 15 more
- Volunteers
- 242 people
- Sponsor
- Novartis Pharmaceuticals
Breast Neoplasm
Neoadjuvant Chemotherapy + Herceptin in HER2 Positive Stage II-III Breast Cancer Patients
The purpose of this study is to evaluate the effectiveness and tolerability of the combination of the following medications given every two weeks in HER2 positive breast cancer patients: trastuzumab (Herceptin) epirubicin…
- Trial name
- NCT00270894
- Testing
- epirubicin, cyclophosphamide, docetaxel
- Where
- 7 sites in United States
- Volunteers
- 30 people
- Sponsor
- Accelerated Community Oncology Research Network
Breast Cancer
Surgical Resection With or Without Axillary Lymph Node Dissection in Treating Women With Node-Negative Breast Cancer and Sentinel Lymph Node Micrometastases
RATIONALE: Surgery to remove lymph nodes in the armpit in patients with sentinel lymph node micrometastases may remove cancer cells that have spread from tumors in the breast.
- Trial name
- 23-01 (NCT00072293)
- Testing
- Axillary lymph node dissection, No axillary lymph node dissection
- Where
- 31 sites in Australia, Belgium and 8 more
- Volunteers
- 931 people
- Sponsor
- ETOP IBCSG Partners Foundation
Breast Cancer, Breast Carcinoma
A Study to Describe the Breast Cancer Patient Population, Treatment, and Results in Indian Patients Receiving Combinations of the Medicines Called Palbociclib for Advanced Breast Cancer
The purpose of this clinical study is to describe the patient population, breast cancer treatment, and breast cancer treatment results of adult female patients who have received palbociclib combination treatments for advanced or…
- Conditions
- Breast Cancer, Breast Carcinoma, Breast Neoplasms, Breast Tumors
- Trial name
- NCT05584644
- Testing
- Palbociclib plus hormonal treatment - first line treatment, Palbociclib plus hormonal treatment - second line treatment
- Where
- 6 sites in India
- Volunteers
- 150 people
- Sponsor
- Pfizer
Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma
Testing the Addition of an Anti-cancer Drug, Copanlisib, to the Usual Maintenance Treatment (Trastuzumab and Pertuzumab) After Initial Chemotherapy in a Phase Ib/II Trial for Advanced HER2 Positive Breast Cancer
This phase Ib/II trial studies the side effects and best dose of copanlisib when given together with trastuzumab and pertuzumab and to see how well they work after induction treatment in treating patients with HER2 positive stage…
- Conditions
- Anatomic Stage IV Breast Cancer AJCC v8, HER2-Positive Breast Carcinoma, Metastatic Breast Carcinoma
- Trial name
- NCT04108858
- Testing
- Copanlisib, Pertuzumab, Trastuzumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
A Study of Trastuzumab Emtansine (T-DM1) Sequentially With Anthracycline-based Chemotherapy, as Adjuvant or Neoadjuvant Therapy for Patients With Early Stage Herceptin (HER)2-positive Breast Cancer
This single-arm open-label study assessed the safety, feasibility, and efficacy of trastuzumab emtansine (T-DM1) after the completion of anthracycline-based adjuvant/neoadjuvant chemotherapy in patients with early HER2-positive…
- Trial name
- NCT01196052
- Testing
- Trastuzumab emtansine
- Where
- 44 sites in United States, Belgium and 6 more
- Volunteers
- 153 people
- Sponsor
- Hoffmann-La Roche
Advanced, Androgen Receptor Positive Triple Negative Breast Cancer
Safety and Efficacy Study of Enzalutamide in Patients With Advanced, Androgen Receptor-Positive, Triple Negative Breast Cancer
The purpose of this study is to determine if enzalutamide is safe and effective in the treatment of patients with advanced breast cancer that express the androgen receptor but do not express the estrogen or progesterone receptor…
- Trial name
- NCT01889238
- Testing
- Enzalutamide
- Where
- 132 sites in United States, Belgium and 5 more
- Volunteers
- 118 people
- Sponsor
- Pfizer
Breast Cancer
Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer
The study drug cabozantinib works by inhibiting several different proteins which are believed to be involved in breast cancer tumor growth, its ability to spread, and its ability to form new blood vessels.
- Trial name
- NCT01441947
- Testing
- Cabozantinib, Fulvestrant
- Where
- 4 sites in United States
- Volunteers
- 68 people
- Sponsor
- Massachusetts General Hospital
HER2 Positive Breast Cancer
A Study of Tucatinib Plus Trastuzumab Deruxtecan in HER2+ Breast Cancer
This trial studies how well the drug tucatinib works when given with trastuzumab deruxtecan (T-DXd). It will also look at what side effects happen when these drugs are given together.
- Trial name
- HER2CLIMB-04 (NCT04539938)
- Testing
- tucatinib, trastuzumab deruxtecan
- Where
- 140 sites in United States
- Volunteers
- 70 people
- Sponsor
- Seagen, a wholly owned subsidiary of Pfizer
Breast Neoplasms, Neoplasm Metastasis
A Study of Imlunestrant, Investigator's Choice of Endocrine Therapy, and Imlunestrant Plus Abemaciclib in Participants With ER+, HER2- Advanced Breast Cancer
The main purpose of this study is to measure how well imlunestrant works compared to standard hormone therapy, and how well imlunestrant with abemaciclib work compared to imlunestrant in participants with breast cancer that is…
- Trial name
- EMBER-3 (NCT04975308)
- Testing
- Imlunestrant, Exemestane, Fulvestrant
- Where
- 243 sites in United States, Argentina and 20 more
- Volunteers
- 874 people
- Sponsor
- Eli Lilly and Company
Breast Cancer
Docetaxel in Node Positive Adjuvant Breast Cancer
The purpose of this study was to compare disease-free survival after treatment with docetaxel in combination with doxorubicin and cyclophosphamide to 5-fluorouracil in combination with doxorubicin and cyclophosphamide in operable…
- Trial name
- TAX316 (NCT00688740)
- Testing
- Docetaxel, 5-fluorouracil, Doxorubicin
- Where
- 20 sites in United States, Argentina and 18 more
- Volunteers
- 1,491 people
- Sponsor
- Sanofi
Estrogen Receptor Negative, Estrogen Receptor Positive
Paclitaxel, Nab-paclitaxel, or Ixabepilone With or Without Bevacizumab in Treating Patients With Stage IIIC or Stage IV Breast Cancer
This randomized phase III trial studies the side effects and how well different chemotherapy regimens with or without bevacizumab work in treating patients with stage IIIC or stage IV breast cancer.
- Conditions
- Estrogen Receptor Negative, Estrogen Receptor Positive, HER2/Neu Negative, HER2/Neu Positive
- Trial name
- NCT00785291
- Testing
- Bevacizumab, Ixabepilone, Laboratory Biomarker Analysis
- Where
- 704 sites in United States, Puerto Rico
- Volunteers
- 799 people
- Sponsor
- National Cancer Institute (NCI)
Breast Cancer
DWI in Assessing Treatment Response in Patients With Breast Cancer Receiving Neoadjuvant Chemotherapy
RATIONALE: Imaging procedures, such as diffusion-weighted magnetic resonance imaging (DWI) and dynamic contrast-enhanced magnetic resonance imaging (DCE-MRI), may help in evaluating how well patients with breast cancer respond to…
- Trial name
- ACRIN6698 (NCT01564368)
- Testing
- diffusion-weighted magnetic resonance imaging
- Where
- 7 sites in United States
- Volunteers
- 406 people
- Sponsor
- American College of Radiology Imaging Network
Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer
Combination Chemotherapy and Filgrastim Before Surgery in Treating Patients With HER2-Positive Breast Cancer That Can Be Removed By Surgery
This phase II trial studies how well giving combination chemotherapy and filgrastim together before surgery works in treating patients with human epidermal growth receptor 2 (HER2)-positive breast cancer that can be removed by…
- Conditions
- Estrogen Receptor-negative Breast Cancer, Estrogen Receptor-positive Breast Cancer, HER2-positive Breast Cancer, Progesterone Receptor-negative Breast Cancer
- Trial name
- NCT00194779
- Testing
- doxorubicin hydrochloride, cyclophosphamide, paclitaxel
- Where
- United States
- Volunteers
- 50 people
- Sponsor
- University of Washington
Breast Cancer
Eribulin With Trastuzumab as First-line Therapy for Locally Recurrent or Metastatic HER2 Positive Breast Cancer
This is a multicenter phase 2 study designed to evaluate the safety and efficacy of eribulin mesylate in combination with trastuzumab as first line treatment in female subjects with locally recurrent or metastatic human epidermal…
- Trial name
- NCT01269346
- Testing
- Eribulin Mesylate
- Where
- 26 sites in United States
- Volunteers
- 52 people
- Sponsor
- Eisai Inc.
Breast Cancer
Caelyx, Cyclophosphamide and Herceptin in Patients With Metastatic Breast Cancer
Eligible patients must receive Caelyx plus Cyclophosphamide plus Herceptin for 6 cycles that will be administered every 4 weeks.
- Trial name
- NCT00258960
- Testing
- Liposomal Doxorubicin, Cyclophosphamide, Trastuzumab
- Where
- 12 sites in Spain
- Volunteers
- 49 people
- Sponsor
- Spanish Breast Cancer Research Group
Breast Cancer
Arimidex With or Without Faslodex In Postmenopausal Women With HR Positive Breast Cancer
Over the last 3 decades, a steady shift has occurred in the management of breast cancer. Because it was traditionally viewed as a local disease, many advocated the use of radical surgery to achieve maximum survival benefit.
- Trial name
- PACT001 (NCT00570323)
- Testing
- Arimidex, Faslodex
- Where
- United States
- Volunteers
- 72 people
- Sponsor
- Mothaffar Rimawi